secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095433
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Q2 net loss $28.8M; cash $346.2M; RMAT designations for KYV-101
-----------------------------------------------------------------------

- Q2 net loss $28.8M ($0.67 per share) vs $13.1M loss year ago.
- Cash, equivalents & marketable securities $346.2M as of June 30, 2024.
- No severe ICANS or CRS Grade ≥3 in 36 autoimmune patients treated with KYV-101.
- 100% manufacturing success for KYV-101 across 36 patients.
- Received FDA RMAT designations for Stiff-Person Syndrome and Myasthenia Gravis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024095433/0000950170-24-095433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024095433/kytx-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer